Co-immunization with DNA vaccines encoding yidR and IL-17 augments host immune response against Klebsiella pneumoniae infection in mouse model

References

• Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–12. doi: 10.1038/s41579-019-0315-1
   PubMed Web of Science ®Google Scholar
• Huang T, Lv Z, Lin J, et al. A potent antibiotic combination of linezolid and polymycin b nonapeptide against Klebsiella pneumoniae infection in vitro and in vivo. Front Pharmacol. 2022;13:887941. doi: 10.3389/fphar.2022.887941
   PubMed Web of Science ®Google Scholar
• Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense. Microbiol Mol Biol Rev. 2016;80(3):629–661. doi: 10.1128/MMBR.00078-15
   PubMed Web of Science ®Google Scholar
• Martin RM, Colonization BM. Infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. doi: 10.3389/fcimb.2018.00004
   PubMed Web of Science ®Google Scholar
• Tan S, Gao J, Li Q, et al. Synergistic effect of chlorogenic acid and levofloxacin against Klebsiella pneumonia infection in vitro and in vivo. Sci Rep. 2020;10(1):20013. doi: 10.1038/s41598-020-76895-5
   PubMed Web of Science ®Google Scholar
• Rodrigues MX, Yang Y, de Souza Meira EB, et al. Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection. Vaccine. 2020;38(29):4640–4648. doi: 10.1016/j.vaccine.2020.03.057
   PubMed Web of Science ®Google Scholar
• Feldman MF, Mayer Bridwell AE, Scott NE, et al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc Natl Acad Sci USA. 2019;116(37):18655–18663. doi: 10.1073/pnas.1907833116
   PubMed Web of Science ®Google Scholar
• Assoni L, Girardello R, Converso TR, et al. Current stage in the development of Klebsiella pneumoniae vaccines. Infect Dis Ther. 2021;10(4):2157–2175. doi: 10.1007/s40121-021-00533-4
   PubMed Web of Science ®Google Scholar
• Choi M, Tennant SM, Simon R, et al. Progress towards the development of klebsiella vaccines. Expert Rev Vaccines. 2019;18(7):681–691. doi: 10.1080/14760584.2019.1635460
   PubMed Web of Science ®Google Scholar
• Ahmad TA, El-Sayed LH, Haroun M, et al. El Ashry el SH. Development of immunization trials against Klebsiella pneumoniae. Vaccine. 2012;30(14):2411–2420. doi: 10.1016/j.vaccine.2011.11.027
   PubMed Web of Science ®Google Scholar
• Datta D, Bansal GP, Gerloff DL, et al. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine. 2017;35(2):264–272. doi: 10.1016/j.vaccine.2016.11.072
   PubMed Web of Science ®Google Scholar
• Huang T, Zhao K, Song X, et al. Heterologous prime-boost immunization with DNA vaccine and modified recombinant proteins enhances immune response against Trueperella pyogenes in mice. Vaccines (Basel). 2022;10(6):839. doi: 10.3390/vaccines10060839
   PubMed Web of Science ®Google Scholar
• Silveira MM, Moreira G, Mendonça M. DNA vaccines against COVID-19: perspectives and challenges. Life Sci. 2021;267:118919. doi: 10.1016/j.lfs.2020.118919
   PubMed Web of Science ®Google Scholar
• Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15(3):313–329. doi: 10.1586/14760584.2016.1124762
   PubMed Web of Science ®Google Scholar
• Kurupati P, Ramachandran NP, Poh CL. Protective efficacy of DNA vaccines encoding outer membrane protein a and OmpK36 of Klebsiella pneumoniae in mice. Clin Vaccine Immunol. 2011;18(1):82–88. doi: 10.1128/CVI.00275-10
   PubMed Web of Science ®Google Scholar
• Yang Y, Higgins CH, Rehman I, et al. Genomic diversity, virulence, and antimicrobial resistance of klebsiella pneumoniae strains from cows and humans. Appl Environ Microbiol. 2019;85(6):e02654–18. doi: 10.1128/AEM.02654-18
   PubMed Web of Science ®Google Scholar
• Lin JS, Kummer LW, Szaba FM, et al. IL-17 contributes to cell-mediated defense against pulmonary yersinia pestis infection. J Immunol. 2011;186(3):1675–1684. doi: 10.4049/jimmunol.1003303
   PubMed Web of Science ®Google Scholar
• Chen K, Eddens T, Trevejo-Nunez G, et al. IL-17 receptor signaling in the lung epithelium is required for mucosal chemokine gradients and pulmonary host defense against K. pneumoniae. Cell Host Microbe. 2016;20(5):596–605. doi: 10.1016/j.chom.2016.10.003
   PubMed Web of Science ®Google Scholar
• Iwanaga N, Chen K, Yang H, et al. Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling. Sci Immunol. 2021;6(63):eabf1198. doi: 10.1126/sciimmunol.abf1198
   PubMed Web of Science ®Google Scholar
• Nemattalab M, Shenagari M, Taheri M, et al. Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866. doi: 10.1016/j.cyto.2019.154866
   PubMed Web of Science ®Google Scholar
• Gonçalves VS, Santos FDS, Dos Santos Junior AG, et al. Recombinant bovine IL17A acts as an adjuvant for bovine herpesvirus vaccine. Res Vet Sci. 2021;136:185–191. doi: 10.1016/j.rvsc.2021.02.014
   PubMed Web of Science ®Google Scholar
• Zhao K, Li W, Li J, et al. TesG is a type I secretion effector of Pseudomonas aeruginosa that suppresses the host immune response during chronic infection. Nat Microbiol. 2019;4(3):459–469. doi: 10.1038/s41564-018-0322-4
   PubMed Web of Science ®Google Scholar
• Huang T, Zhao K, Zhang Z, et al. DNA vaccination based on pyolysin co-immunized with IL-1β enhances host antibacterial immunity against Trueperella pyogenes infection. Vaccine. 2016;34(30):3469–3477. doi: 10.1016/j.vaccine.2016.04.025
   PubMed Web of Science ®Google Scholar
• Chehelgerdi M, Doosti A. Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine. J Nanobiotechnology. 2020;18(1):63. doi: 10.1186/s12951-020-00618-1
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun X, Huang X, et al. Nanoparticles of chitosan/poly(D,L-Lactide-Co-Glycolide) enhanced the immune responses of Haemonchus contortus HCA59 antigen in model mice. Int J Nanomedicine. 2021;16:3125–3139. doi: 10.2147/IJN.S301851
   PubMed Web of Science ®Google Scholar
• Boettler T, Csernalabics B, Salié H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol. 2022;77(3):653–659. doi: 10.1016/j.jhep.2022.03.040
   PubMed Web of Science ®Google Scholar
• Huang T, Song X, Jing J, et al. Chitosan-DNA nanoparticles enhanced the immunogenicity of multivalent DNA vaccination on mice against Trueperella pyogenes infection. J Nanobiotechnology. 2018;16(1):8. doi: 10.1186/s12951-018-0337-2
   PubMedGoogle Scholar
• Facchini M, De Fino I, Riva C, et al. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014;2014(85). doi: 10.3791/51019-v
   Google Scholar
• Huang T, Pu Q, Zhou C, et al. MicroRNA-302/367 Cluster impacts host antimicrobial defense via regulation of mitophagic response against Pseudomonas aeruginosa Infection. Front Immunol. 2020;11:569173. doi: 10.3389/fimmu.2020.569173
   PubMed Web of Science ®Google Scholar
• Bergamini G, Perico ME, Di Palma S, et al. Mouse pneumonia model by Acinetobacter baumannii multidrug resistant strains: comparison between intranasal inoculation, intratracheal instillation and oropharyngeal aspiration techniques. PLOS ONE. 2021;16(12):e0260627. doi: 10.1371/journal.pone.0260627
   PubMed Web of Science ®Google Scholar
• Li X, Zhou X, Ye Y, et al. Lyn regulates inflammatory responses in Klebsiella pneumoniae infection via the p38/NF-κB pathway. Eur J Immunol. 2014;44(3):763–773. doi: 10.1002/eji.201343972
   PubMed Web of Science ®Google Scholar
• Eveillard M, Soltner C, Kempf M, et al. The virulence variability of different acinetobacter baumannii strains in experimental pneumonia. J Infect. 2010;60(2):154–161. doi: 10.1016/j.jinf.2009.09.004
   PubMed Web of Science ®Google Scholar
• Lundberg U, Senn BM, Schüler W, et al. Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae. Hum Vaccin Immunother. 2013;9(3):497–505. doi: 10.4161/hv.23225
   PubMed Web of Science ®Google Scholar
• Lee WH, Choi HI, Hong SW, et al. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med. 2015;47(9):e183. doi: 10.1038/emm.2015.59
   PubMedGoogle Scholar
• Berretta F, St-Pierre J, Piccirillo CA, et al. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol. 2011;186(8):4862–4871. doi: 10.4049/jimmunol.1003777
   PubMed Web of Science ®Google Scholar
• Soni B, Singh S. Cytokine milieu in infectious disease: a sword or a boon? J Interferon Cytokine Res. 2020;40(1):24–32. doi: 10.1089/jir.2019.0089
   PubMed Web of Science ®Google Scholar
• Rangasamy T, Ghimire L, Jin L, et al. Host Defense against Klebsiella pneumoniae pneumonia is augmented by lung-derived mesenchymal stem cells. J Immunol. 2021;207(4):1112–1127. doi: 10.4049/jimmunol.2000688
   PubMed Web of Science ®Google Scholar